MHRA Peptide Regulatory Tracker
Continuous statutory monitoring archive of Medicines and Healthcare products Regulatory Agency (MHRA) enforcement activities, border interdictions, safety alerts, and compliance warning letters concerning synthetic peptides and research chemical supply lines across the United Kingdom.
Recent Regulatory Enforcement Precedents
Detailed case reviews of recent enforcement actions by the MHRA, Advertising Standards Authority, and UK Border Force establishing statutory boundaries for research peptide commerce.
Conditional Approval: Semaglutide (Wegovy) for Non-Cirrhotic MASH Liver Fibrosis
MHRA grants conditional marketing authorization for semaglutide to treat adult patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced hepatic scarring.
National Warning: Public Advertising Prohibition on Licensed & Unlicensed GLP-1 and Peptides
MHRA, ASA and GPhC jointly caution commercial entities against promoting prescription-only or unlicensed research peptides directly to consumers.
First Oral Peptide Tablet Approved for UK Weight Management (Prescription Only)
MHRA clears oral formulation of GLP-1 receptor agonist under strict POM classification, reiterating ban on general public advertising.
Criminal Enforcement: Interception of 12,000 Unlicensed Doses Including Retatrutide & Peptides
Special Investigations Unit carried out arrests and recovered 12,000 doses of unlicensed synthetic peptides manufactured without GMP standards.
High Court ISP Block Order: Dynamic Web Filtering for Counterfeit Peptide Portals
High Court orders top UK internet providers to implement dynamic domain filtering against rogue illicit drug websites supplying unapproved peptide vials.
Drug Safety Alert: Falsified Tirzepatide Multidose Cartridges Intercepted
National alert identifying counterfeit batch lots with unverified sterility and non-standard peptide concentrations circulating in grey market supply chains.
Rolling 90-Day Government Notices Archive
Exhaustive record of official Drug Safety Updates, enforcement bulletins, and regulatory announcements published by the MHRA.
| Date | Category | Official Document Title | Access |
|---|---|---|---|
| 2026-10-01 | ANNOUNCEMENT | MHRA regulatory notice on microphysiological systems and in vitro non-animal assays for synthetic peptide characterization | gov.uk |
| 2026-09-24 | ENFORCEMENT | MHRA Special Investigations Unit: Enforcement against counterfeit peptide and unlicensed compounding supply operations | gov.uk |
| 2026-09-18 | DRUG SAFETY UPDATE | MHRA Drug Safety Bulletin: Verification requirements for reconstituted peptides and bacterial endotoxin limits | gov.uk |
| 2026-09-08 | ANNOUNCEMENT | MHRA Borderline Section Note: Clarification on synthetic peptides marketed with physiological claims vs in vitro research chemicals | gov.uk |
| 2026-08-28 | ENFORCEMENT | Border Force and MHRA joint operation intercepts multi-kilogram batches of unverified synthetic peptides lacking COAs | gov.uk |
| 2026-08-18 | DRUG SAFETY UPDATE | MHRA Drug Safety Update: Storage requirements and cold-chain thermal stability thresholds for lyophilized peptides | gov.uk |
| 2026-08-05 | ANNOUNCEMENT | MHRA & ASA Joint Compliance Notice: Enforcement of CAP Code Rule 12.11 regarding unlicensed research chemical advertising | gov.uk |
| 2026-07-28 | DRUG SAFETY UPDATE | MHRA Drug Safety Bulletin: GLP-1 receptor agonist safety monitoring and reporting protocols | gov.uk |
| 2026-07-19 | ENFORCEMENT | Trading Standards and MHRA coordinated warning notices issued to unauthorized domestic peptide compounding laboratories | gov.uk |
| 2026-07-12 | DRUG SAFETY UPDATE | MHRA Drug Safety Update: Analytical verification standards for Solid-Phase Peptide Synthesis (SPPS) reagents | gov.uk |
| 2026-07-08 | ANNOUNCEMENT | WADA Prohibited List annual harmonization: Reaffirming S0 and S2 classification for peptide secretagogues and growth factors | gov.uk |
| 2026-07-03 | ANNOUNCEMENT | MHRA grants conditional marketing authorization for semaglutide in non-cirrhotic MASH hepatic fibrosis | gov.uk |
| 2026-06-25 | DRUG SAFETY UPDATE | MHRA Drug Safety Alert: Falsified tirzepatide cartridges intercepted in unauthorized supply chains | gov.uk |
| 2026-06-18 | ENFORCEMENT | MHRA, ASA and GPhC national enforcement directive on unauthorized promotion of licensed and unlicensed peptides | gov.uk |